2025
Optimizing post–chimeric antigen receptor (CAR) T cell monitoring: Evidence across lisocabtagene maraleucel (liso-cel) pivotal clinical trials and real-world experience.
Kamdar M, Shadman M, Ahmed S, Abramson J, Perales M, Ahmed N, Mirza S, Isufi I, Frigault M, Crombie J, Miklos D, Vasconcelos A, Crotta A, Bernasconi D, Roy D, Bleickardt E, Pasquini M, Hunter B, Lunning M. Optimizing post–chimeric antigen receptor (CAR) T cell monitoring: Evidence across lisocabtagene maraleucel (liso-cel) pivotal clinical trials and real-world experience. Journal Of Clinical Oncology 2025, 43: 7026-7026. DOI: 10.1200/jco.2025.43.16_suppl.7026.Peer-Reviewed Original ResearchStandard of careLiso-celPivotal clinical trialsMedian durationClinical trialsR/R LBCLCenter for International Blood and Marrow Transplant Research (CIBMTR) registryCAR-T cell therapyB-cell NHLT-cell therapyT-cell monitoringLisocabtagene maraleucelCause of deathAntigen receptorB cellsCIBMTRInfusionLBCLRegistryLow gradeTrialsR/RMedianDurationDays
2024
Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML
Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Goshua G, Bewersdorf J, Zeidan A. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Leukemia & Lymphoma 2024, 66: 488-496. PMID: 39560957, PMCID: PMC12138910, DOI: 10.1080/10428194.2024.2426073.Peer-Reviewed Original ResearchConventional care regimensOlder patientsTreatment of older patientsIDH2 inhibitor enasidenibIncremental cost-effectiveness ratioCost-effectiveness ratioProbabilistic sensitivity analysesR/R AMLRefractory/relapsed AMLEvent-freeCost-effective treatmentEnasidenibCare regimensAMLPatientsCost-effectiveIncremental costLife yearsConventional careR/RIncremental effectSurvivalTreatmentHMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
Chin K, Derkach A, Famulare C, Gupta G, Borge P, Geyer M, Goldberg A, Haque T, Park J, Roeker L, Tallman M, Stahl M, Stein E. HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML. Leukemia & Lymphoma 2024, 66: 270-278. PMID: 39397429, DOI: 10.1080/10428194.2024.2411436.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaTreatment modificationHypomethylating agentsResponse rateAssociated with lower response ratesMedian overall survivalIDH-mutated acute myeloid leukemiaLong-term toxicityCR/CRi rateSignificant neutropeniaFebrile neutropeniaInduction chemotherapyOverall survivalMyeloid leukemiaLow response rateSurvival rateAffect SurvivalNeutropeniaVenetoclaxSurvivalED visitsPatientsR/RMonthsReal-world settings
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply